The CME activity for this article is forthcoming. Access and take the CME test online and
receive 1 hour of AMA PRA category 1 credit at CME. TheOncologist. com Gefitinib (Iressa®; …

Gefitinib and erlotinib, small-molecule tyrosine kinase inhibitors (TKIs) of the epidermal
growth factor receptor (EGFR), were the first molecularly targeted agents to become …

The development of orally active small molecule inhibitors of the epidermal growth factor
receptor (EGFR) has led to new treatment options for non-small cell lung cancer (NSCLC) …

Abstract Learning Objectives After completing this course, the reader will be able to:
Describe the EGFR signaling pathway as a target for new anticancer agents. Characterize …

The epidermal growth factor receptor (EGFR) is overexpressed in the majority of non–small-
cell lung cancers (NSCLCs). This presents an opportune target for new treatment strategies …

Introduction: EGFR is the receptor for epidermal growth factor (EGF) and belongs to the
protein tyrosine kinase (PTK) receptor. It is closely related to the inhibition of tumor cell …

Background: Lung cancer is one of the leading cause of cancer death worldwide, the most
common histological type of lung cancer is non-small cell lung cancer (NSCLC), whose …

In the last 5 years the epidermal growth factor receptor (EGFR) has emerged as one of the
most important targets for drug development in oncology. Monoclonal antibodies targeting …

Highlights•Comprehensive review of EGFRTK inhibitors.•Helps in understanding the
structural and developmental aspects of small molecular EGFR TKIs.•Focuses on mutant …

The discovery of “driver” genomic alterations in patients with non‐small cell lung cancer
(NSCLC) has dramatically changed the field of thoracic oncology in recent years. The best …